Loading...
NPI 1952519696 · Boise, ID · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Safeway Inc is a community/retail pharmacy provider located in Boise, Idaho. This profile covers 17 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Safeway Inc |
| Address | 250 E Parkcenter Blvd |
| City | Boise |
| State | ID |
| ZIP | 83706 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | May 18, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $76.1M |
| Medicaid | $330 |
SAFEWAY INC is operating as a high-volume community/retail pharmacy in BOISE, ID with a clear service-line emphasis on immunizations and COVID testing. Its top Medicare codes are vaccination and administration codes (91322, 90662, 91320, 90480, G0008) and a high-volume self-test supply code (K1034), with examples including 90662 at 197.4K claims and $14.2M revenue and 91322 at 100.1K claims and $14.3M revenue, indicating large-scale, retail-based vaccine delivery and test distribution. Analysts should interpret the code mix as typical of a pharmacy chain that executes mass vaccination and OTC test provisioning rather than a clinician-driven procedural practice.
Medicare revenue is the dominant payer for this provider, totaling $76.1M compared with just $331 in lifetime Medicaid revenue; the Medicare portfolio drives nearly all reported billing volume and dollars. Revenue concentration within Medicare is notable: the precomputed top 3 Medicare codes (91322, 90662, 91320) account for 53.5% of the provider's total Medicare revenue, signaling that a few vaccine products are the primary commercial drivers of the Medicare business. This concentration suggests that payer negotiations or reimbursement changes for those vaccine codes would disproportionately affect overall revenue.
SAFEWAY INC shows national-scale dominance on several vaccine codes: 90662 ranks #1 of 70752 providers nationally (100th percentile) and 91322 ranks #2 of 29357 providers nationally (100th percentile), both labeled as extreme outliers versus typical national volumes. Multiple other immunization and administration codes also appear at the 100th percentile or near it (91320 #2 of 27083, 90480 #2 of 46950, G0008 #3 of 119096), which positions the provider as a major national outlier in Medicare vaccine administration and inventory distribution. For payer and competitive analyses, these ranks indicate SAFEWAY INC functions as a top-tier outlet for Medicare beneficiaries seeking routine and seasonal vaccinations.
K1034 (nonprescription self-administered COVID test provision) is a standout operational line with 953.3K claims and $11.4M revenue and is reported as an extreme outlier (rank #46 of 30143 nationally, 100th percentile). This single test code's claim volume exceeds many vaccine codes in claim counts and represents a substantial component of non-vaccine Medicare services; it highlights a significant retail testing distribution operation that buyers and utilization reviewers should track separately from vaccine administration.
Although Medicaid billing exists on record, it is effectively negligible in scale: lifetime Medicaid revenue is $331 while the listed Medicaid top code 90686 shows $341 and is precomputed to represent 100.0% of Medicaid revenue. The Medicaid entry for 90686 is ranked #119 of 164 in-state (28th percentile) and described as typical and unremarkable, which reinforces that SAFEWAY INC is not a material Medicaid provider in Idaho and that Medicaid-specific network or rate considerations will have minimal financial impact.
Several high-dollar pneumococcal and influenza vaccine products also contribute meaningfully to Medicare revenue beyond the top three, for example 90677 with $4.6M revenue (16.2K claims) and G0008 with $6.9M revenue (216.5K claims). These codes appear at high national ranks (90677 #3 of 52451, G0008 #3 of 119096) and underscore that the provider’s Medicare business is diversified across multiple vaccine types, not solely limited to COVID vaccines. For formulary, inventory, and cold-chain planning, payers should note both the breadth (multiple distinct vaccine products) and depth (high claim counts) of immunization services.
The provider has been enumerated with an NPI since 2007-05-18 (~19 years ago), indicating long-standing presence in administrative registries; this tenure, combined with the very large Medicare vaccination and testing volumes, supports the interpretation of an established, ongoing retail operation rather than a short-term program. For payer analysts evaluating network continuity or contracting, the longevity plus extreme national ranks on key codes argue for stable, repeatable service capacity.
From a payer risk and network-management perspective, SAFEWAY INC represents a concentrated, Medicare-focused retail immunization and testing node: top-3 Medicare codes account for 53.5% of Medicare revenue, many vaccine and administration codes are extreme outliers nationally, and K1034 shows massive test distribution volume. Conversely, the provider’s Medicaid footprint is minimal and not regionally dominant (90686 at the 28th in-state percentile), so payer strategies tied to Medicaid will likely have limited returns while Medicare-focused strategies around vaccination logistics, reimbursement, and utilization management are the most material.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 100,130 | $140 | $14.3M |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 197,370 | $70 | $14.2M |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 96,600 | $130 | $12.4M |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 953,350 | $10 | $11.4M |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 196,670 | $40 | $8.5M |
| G0008 | Administration of influenza virus vaccine | 216,540 | $30 | $6.9M |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 16,210 | $280 | $4.6M |
| 0124A | N/A | 33,140 | $40 | $1.4M |
| 0134A | N/A | 29,590 | $40 | $1.3M |
| 90682 | This code represents a quadrivalent flu vaccine given by injection into the muscle. The vaccine is made using recombinant DNA technology and contains only a protein from the virus. It does not… | 7,670 | $70 | $552K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 30 | $10 | $340 |
How this provider's Medicaid billing volume and revenue compare to other Idaho providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Idaho median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 119 | 160 | 110 | $1 | $2K |
Other providers in the same ZIP code as Safeway Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Albertsons LLC | ID | Community/Retail Pharmacy | $29M | $0 |
| American Drug Stores LLC | ID | Community/Retail Pharmacy | $27.3M | $0 |
| Vons Companies Inc | ID | Community/Retail Pharmacy | $12.7M | $0 |
| Nai Saturn Eastern LLC | ID | Community/Retail Pharmacy | $12.6M | $0 |
| Smiles 4 Kids | ID | Dentist | $0 | $9.6M |
| Acme Markets Inc | ID | Community/Retail Pharmacy | $9.5M | $0 |
| Randalls Food & Drugs LP | ID | Community/Retail Pharmacy | $6.7M | $0 |
| Shaws Supermarkets Inc | ID | Community/Retail Pharmacy | $5.5M | $0 |
| Saint Alphonsus Regional Medical Center Inc | ID | General Acute Care Hospital | $0 | $5.1M |
| Tdandc LLC | ID | Home Health Agency | $0 | $4.9M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.